🇺🇸

Index Intelligence

· daily

S&P 500 Consumer Staples Sector SEC Filings — March 24, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (broadly encompassing food, beverages, household, personal care, and adjacent sectors), dominant themes include neutral-to-positive compliance assertions in 15+ mortgage trusts (e.g., Benchmark, JPMDB, CF series), signaling stable ABS servicing with no material non-compliance. Period-over-period trends show mixed performance: robust growth in outliers like Cadeler A/S (profit +330% YoY to €280M, EBITDA +238% to €425M) and Select Water Solutions (segment revenues +19% YoY), contrasted by declines in G-III Apparel (net sales -7% YoY to $2.96B, op profit -63%) and Velo3D (Q4 rev -25% YoY, gross margin -73.6%). Capital allocation highlights dividend declarations (Braemar Hotels) and debt refinancings (Moog +5.5% notes, Kodiak 5.875% notes), while M&A speculation emerges in Estée Lauder (potential Puig merger, materiality 9/10). Portfolio-level patterns reveal 6/10 high-materiality filings with mixed sentiment due to growth-margin tradeoffs, 12+ proxy statements clustering AGMs in May 2026 for governance catalysts, and financing inflows supporting expansion amid rising indebtedness (e.g., Cadeler debt to €1.46B). Overall, actionable intelligence points to monitoring beauty M&A and energy-adjacent growth amid apparel weakness, with no widespread insider selling but leadership transitions signaling potential volatility.

39 high priority 11 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 24, 2026

Across 50 filings in the USA S&P 500 Industrials intelligence stream (broadly encompassing aerospace, defense, machinery, transportation, construction, with extraneous financial/mortgage trusts and proxies), overarching themes include routine Regulation AB compliance affirmations in 15+ mortgage trusts (all neutral/positive, no non-compliance), proxy season ramp-up for May 2026 AGMs (10+ filings), and mixed financial results in operating companies highlighting resilience in transportation (C.H. Robinson EPS +25.1% YoY despite revenues -8.4%) amid broader sector softness. Period-over-period trends reveal divergent performance: explosive growth in niche players like Cadeler A/S (profit +330% YoY to €280.2M, EBITDA +238%) and Fennec Pharmaceuticals (product sales +50% YoY to $44.6M), contrasted by declines in apparel/transport (G-III sales -7% YoY, Neurogene net loss widened 20% YoY to $90.4M). No insider trading activity disclosed across filings, limiting conviction signals; capital allocation shows distributions funded by cash flows (Cantor Fitzgerald) or proceeds (Strategic Storage +8.6% YoY), with debt increases (Cadeler net indebtedness +181% to €1.46B). Critical developments include M&A discussions (Estée Lauder/Puig), leadership transitions (Bitcoin Depot new CEO, QuidelOrtho CLO), and clinical catalysts (Neurogene Embolden trial dosing Q2 2026). Portfolio-level patterns flag Industrials outperformance in profitability metrics vs. revenue (e.g., C.H. Robinson ops income +18.8% YoY), with opportunities in undervalued turnarounds amid proxy-driven governance focus.

30 high priority 20 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 24, 2026

Across the S&P 500 Energy sector filings, key themes include management continuity at Chesapeake Utilities (CPK) via a seamless CFO transition and Devon's proactive balance sheet strengthening through credit extension and merger progress with Coterra. No period-over-period declines, flat metrics, or adverse financial trends were reported in any filing, signaling operational stability amid positive sentiments in 2/3 filings. Devon's dual filings highlight material catalysts: a tax-free merger targeted for Q2 2026 close and credit maturity extension to March 24, 2031, with potential borrowing cost reductions via 10bps SOFR spread removal. CPK's executive change underscores confidence in sustained earnings growth and balance sheet strength post-transition on July 1, 2026. Portfolio-level implications point to improving liquidity and M&A momentum in oil & gas E&P, positioning Devon as a sector consolidator while CPK exemplifies utility-like stability in energy distribution. Overall, bullish undertones dominate with no guidance cuts or insider selling detected.

2 high priority 1 medium 3 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 24, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily small/mid-cap and trusts with DJ30-adjacent themes like Intel, eBay), overarching themes include biotech regulatory catalysts, SPAC/M&A pursuits, private credit expansions, energy trust depletions, and governance proxies. Period-over-period trends reveal bimodal patterns: explosive growth in AI/biotech (Blaize revenue +24x YoY to $38.6M, Audax portfolio +46% to $949.8M) contrasted by sharp declines in energy royalties (MV Oil income -39% YoY to $11.3M, VOC -37% to $8.6M) and biotech losses (Achieve +37% to $54.6M). Credit funds show portfolio growth but yield compression (Audax 8.28% vs 10.07% prior), while SPACs highlight PIPE evaluations amid redemption risks. Critical developments: Achieve PDUFA June 20 2026, Blaize FY26 $130M revenue guide, Thermon/CECO merger synergies for 20%+ EBITDA. Portfolio-level patterns: 6/10 high-materiality mixed sentiments driven by cash raises vs burns; capital allocation favors distributions (Golub $0.1875/share) over buybacks; no widespread insider trading but heavy shelves/ATMs signal dilution risks. Market implications: Bullish AI/biotech catalysts, bearish energy depletion, monitor SPAC closings for volatility.

30 high priority 20 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 24, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Discretionary stream (broadly encompassing retail, services, and adjacent sectors), overarching themes include robust revenue growth in select growth names (avg +50% YoY across 12 cos with data, e.g., FTC Solar +110.5%, Fennec +50%) offset by widening net losses (avg +40% YoY in 10 cos) due to op ex surges (e.g., Achieve +41%) and one-time hits; heavy capital allocation toward buybacks (Robinhood +$1.5B) and dividends (Braemar, Golub); M&A/reorg activity (UniFirst/Cintas H2 2026 close, Fundrise mergers, Digimarc reorg); and a wave of proxy filings signaling April-May 2026 meetings. Period-over-period trends reveal portfolio expansion in credit funds (Audax +46%, HPS +118%) and improving cash in biopharma (Achieve +64% cash), but deteriorating margins in solar/manufacturing amid debt pressures. Critical developments like Achieve's PDUFA June 20, 2026, and FTC Solar's covenant waivers imply near-term catalysts, while multiple CFO resignations at New Mountain entities signal leadership flux. Sector implications point to resilient consumer-related demand (e.g., G Willi Food +6% rev, +29% NI) but vulnerability to costs/debt in cyclical plays, favoring buyback-heavy names for near-term returns.

38 high priority 12 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 24, 2026

Across the USA S&P 500 Healthcare stream's 36 filings, biotech and medtech firms dominate with mixed sentiment: clinical advancements and FDA milestones offset widening net losses (avg +25% YoY across Achieve, Absci, Artelo) driven by 25-40% YoY op ex surges amid flat/declining revenues. S&P 500 heavyweights like Medtronic, Centene, and Thermo Fisher show strategic progress—FDA clearance, leadership promotions, and M&A completion—but face short-term EPS dilution and charges. Cash positions strengthened via financings (e.g., Absci $144M to H1 2028, Achieve $36M up 6% YoY), supporting runways through 2027-2028, while capital allocation leans toward R&D reinvestment over dividends/buybacks. Key portfolio trends: 4/7 core healthcare cos reported loss expansion despite asset growth (avg +5% YoY), with H1-H2 2026 catalysts clustering around PDUFAs, trial data, and launches. Non-health filings (e.g., mortgage trusts, FHLBs) neutral, highlighting compliance and debt issuance but irrelevant to sector. Implications: tactical longs on catalysts, hedge burn risks; relative outperformance in clinical progress vs. financial deterioration.

20 high priority 16 medium 36 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 23, 2026

Across 50 SEC filings dated March 23, 2026, in the USA S&P 500 Consumer Staples stream (with broader context), dominant themes include a surge in proxy statements (DEF 14A/DEFA14A for ~20 companies) preparing for May 2026 annual meetings, M&A and restructuring activity (e.g., CECO-Thermon merger with $40M synergies, RMBI-Farmers $82.4M deal, Honeywell Aerospace spin-off via $10B debt tender), and mixed FY25 financials where reported: revenue growth in outliers like CECO (+39% YoY to $774M, EBITDA +43% to $90M), US Antimony (+163% YoY to $39.3M), but declines in Aspen Aerogels (-40% YoY to $271.1M, $389.6M net loss) and Kimberly-Clark (-2.1% net sales to $16.4B despite +1.7% organic). Consumer Staples highlights show resilience via KMB's 54th consecutive dividend increase and $32B Kenvue acquisition (H2 2026 close), offset by Limoneira's dividend pause for capex. Period-over-period trends reveal volatility (avg reported rev change +300% skewed by small caps, but staples flat/declining), with positive capital allocation in dividends/buybacks absent specifics, and forward catalysts clustering in Q2 2026 (AGMs, mergers). Portfolio implications: Staples defensive amid macro but watch organic growth; alpha in M&A synergies and spin-offs.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 23, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly encompassing aerospace, machinery, and adjacent sectors), key themes include robust M&A and spin-off activity (e.g., Honeywell Aerospace spin, Sealed Air acquisition), SPAC extensions/mergers, and mixed financial results with revenue growth in 7/15 reporting companies averaging +35% YoY (e.g., Arbutus +128%, SolarEdge +31%) offset by persistent losses and cash burn in biotechs/small caps. Period-over-period trends show margin improvements in 5 cases (e.g., Bionano gross margin to 46% from 1%, Cato FY SG&A to 35% from 36%), but declines in others (Core Labs op income -3.6% YoY, Cabaletta net loss +45%). Capital allocation leans toward buybacks/repurchases (Slide $125M, Guardian 1.8M shares) and debt refinancings (Hewlett Packard $2B notes, Waters $3.5B), signaling confidence amid high interest environments. Forward-looking catalysts cluster in 2H 2026 (Phase 3 trials, Nasdaq compliances), with positive regulatory clearances (Faraday SEC no-action) removing overhangs. Portfolio-level, industrials show relative strength in cap allocation vs. small-cap dilution risks, positioning sector for consolidation-driven alpha.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 23, 2026

The five filings for the USA S&P 500 Energy intelligence stream feature routine proxy materials from non-energy firms (Halozyme Therapeutics in biotech, CommScope in telecom, and AParadise SPAC), highlighting a potential data mismatch but analyzed for governance insights; all exhibit neutral sentiment with materiality ranging 2-6/10 and no substantive financial or operational enriched data like YoY/QoQ trends, insider trading, capital allocation, or M&A details disclosed. Overarching themes include upcoming virtual annual meetings in early May 2026 for director elections, advisory compensation votes, and auditor ratifications, signaling standard proxy season kickoff without period-over-period financial comparisons or forward-looking guidance changes. No portfolio-level trends in revenue growth, margins, or ratios identifiable due to lack of metrics; SPAC PFIC statement provides minor positive ordinary earnings of $0.000605 per-share per-day for FY2025 with no capital gains/distributions. Critical developments center on scheduled AGMs as near-term catalysts for governance votes, with low proxy costs (e.g., CommScope $11k) indicating efficient shareholder engagement. Market implications are minimal for energy sector but offer tactical opportunities in voting participation and monitoring board stability across filings.

3 high priority 2 medium 5 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 23, 2026

Across 50 filings from the USA S&P 500 Financials stream (including banks, insurers, asset managers, and related services), dominant themes include elevated M&A activity (10+ filings on mergers like CECO/Thermon, Victory/Janus Henderson, Two Harbors bidding war), mixed 2025 financial performance with revenue growth in 7/15 10-Ks averaging +25% YoY (e.g., Finwise +31% assets, SUNation +26%) but declines in 8/15 averaging -20% (e.g., Aterian -30%, Ashford -6%), and proactive capital allocation via buybacks/dividends (Coeur $750M program, News Corp $1B authorization). Period-over-period trends show margin compression in 6/12 detailed cos (avg -150bps, e.g., Aterian gross margin 568bps drop) offset by strong growth in niche banking/insurance (Finwise NIM 9.23%, Progressive 12% premiums). Insider activity sparse but notable 10b5-1 plans (Avalo execs up to 471k shares) signal potential selling pressure; forward guidance largely raised (CECO +23% rev, Coeur gold prod +80%). Portfolio implications: overweight M&A targets/defenses (Two Harbors $10.75/share bid), monitor cyber/regulatory risks (Heritage incident, Volato delisting), with catalysts clustered Q2-H2 2026 (Phase trials, earnings). Overall bullish on capital returners, cautious on high-burn biotechs/hospitality.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 23, 2026

Across these 10 filings from the S&P 500 Technology stream (including adjacent telecom, SPACs, and outliers like banking), dominant themes include active M&A/SPAC activity (3/10 filings) signaling consolidation, capital raise preparations via shelves and ATM offerings (3/10), and mixed FY2025/2026 financials with revenue growth but profitability challenges. Period-over-period trends show robust top-line growth in Planet Labs (+26% YoY revenue to $307.7M, Adj EBITDA to +$15.5M from -$10.6M) and Richmond Mutual (+23.4% net income to $11.6M, NIM to 2.97% from 2.67%), contrasted by asset quality deterioration (RMBI NPAs to 1.14% from 0.45%) and widened losses (PL net loss to $246.9M from $123.2M). Critical developments like TETE's SPAC merger proxy (low $142K trust signaling high redemptions) and RMBI's bank merger (38% ownership stake post-deal) imply dilution risks and arbitrage potential. Sector implications point to funding pressures amid growth investments, with Planet's deferred revenue surge (+165% to $248.1M) highlighting backlog strength. Portfolio-level, 2/3 detailed financials show margin stability/mixed (PL gross margin -100bps to 56%) but liquidity improvements (PL cash +94% to $229.4M).

5 high priority 5 medium 10 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 23, 2026

Across 12 filings from NASDAQ-100 related entities, dominant themes include regulatory relief (e.g., Faraday Future's SEC investigation closure), banking M&A (RMBI-Farmers merger valued at $82.4M), and frequent dilution via ATM/shelf offerings (Imunon +$7M to $17M, IBS +$3.97M, Comtech $125M shelf), signaling capital needs in small caps. Period-over-period trends show RMBI's standout net income +23.4% YoY to $11.6M and NIM expansion +30bps to 2.97%, but offset by non-performing assets surging to 1.14% from 0.45%; no broad portfolio growth trends emerge due to limited financial disclosures. Critical developments like Faraday's Nasdaq 180-day compliance window (from Mar 20, 2026) and Intel's proxy highlighting 2025 reinvention under CEO Lip-Bu Tan position for catalysts. Portfolio patterns reveal mixed sentiment (positive in 4/12, neutral 6/12, mixed 2/12) with AI/EV focus (Faraday robotics sales 2026 start) and SPAC mergers (TETE low $142k trust signaling redemptions). Implications favor tactical plays in cleared overhangs and mergers, but caution on dilutions and asset quality deterioration.

6 high priority 6 medium 12 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 23, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily blue-chip adjacent with SPAC/M&A focus), dominant themes include heightened M&A and de-SPAC activity (10+ filings: Thermon/CECO, Two Harbors competing bids at $10.70-$10.75/share, Victory/Janus, ReserveOne), mixed financial performance with 7/15 reporting companies showing YoY net income growth or loss narrowing (e.g., AbbVie revenues +8.5% operationally, Finwise +26%, Cato FY loss -67% to $5.9M), but biotechs facing cash burn (Avalo cash -88% to $15.9M, Cabaletta -19% to $133.6M). Period-over-period trends reveal revenue growth averaging +15% YoY in outperformers (Progressive premiums +12%, CECO +39%), offset by margin pressures (Finwise NIM -76 bps to 9.23%) and elevated provisions/expenses; capital allocation leans shareholder-friendly with repurchases (Slide $125M), dividends (AbbVie to $1.73/share), and buybacks implied in strong cash flows. Honeywell's debt tender supports Aerospace spin-off, Faraday Future clears SEC overhang, signaling blue-chip stability amid small-cap volatility. Portfolio implications: overweight M&A targets for premiums, monitor biotech catalysts (Avalo/Cabaletta data Q2/1H26), avoid delisting risks (Volato); overall positive sentiment in 18/50 filings drives near-term upside in select names.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 23, 2026

Across 43 filings in the USA S&P 500 Healthcare stream (with some cross-sector inclusions), proxy statements dominate (e.g., AbbVie, Stryker, Baxter), signaling peak proxy season with governance enhancements like eliminating supermajority voting (AbbVie, Regions) and board refreshes. Healthcare leaders show robust 2025 performance: AbbVie net revenues +8.5% YoY to $61.2B (Growth Platform +19.6% to $56.6B, Skyrizi +50%, Rinvoq +40%), while M&A accelerates with Abbott's $105/share cash acquisition of Exact Sciences completed March 23, 2026. Period-over-period trends reveal revenue growth averaging +10-20% YoY in key reporters (AbbVie +8.5%, Yunhong +10%, Sparta +71% 9M), but mixed profitability with losses widening in biotechs/small caps (Bally's -$666M Successor, Procaccianti net income -10% YoY to $1.9M). Cyber risks emerge (Stryker incident contained but ongoing probe; Heritage unauthorized access), biotech trials positive (Artelo ART27.13 +6.38% weight gain Phase 2a), and capital allocation favors dividends (AbbVie quarterly $1.73/share, +485% TSR decade). Portfolio implications: Bullish on pharma/devices growth/M&A, cautious on cyber/biotech volatility; 5/10 healthcare filings highlight strong op cash flows ($19B AbbVie) vs sector margin stability.

23 high priority 20 medium 43 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 20, 2026

Across 46 filings in the USA S&P 500 Consumer Staples intelligence stream (broadly interpreted to include adjacent defensive sectors like pharma and logistics), dominant themes include robust revenue growth in 6/12 companies reporting financials (avg +100% YoY, e.g., Belpointe PREP +244%, Yellowstone +52%, Cellectis +61.7%), offset by mixed profitability with 4/12 showing widening net losses (avg +60% YoY deterioration). SPAC and M&A activity peaks with Pelican-Greenland merger approval despite 63% redemptions, Constellation-Calpine completion, and pending KORE $9.25/share cash deal, signaling consolidation. Proxy statements (12/46) highlight 2025 successes like Eli Lilly's $65.2B revenue/40% TSR outperformance and Penske's $31.8B revenue/$182M buybacks, fostering bullish sentiment amid AGMs in Apr-May 2026. Risks emerge from Nasdaq bid price deficiencies (Faraday Future, TELA Bio), repeated insider debt extensions (Perfect Moment), and leadership churn (CleanCore CEO resignation). Capital allocation leans shareholder-friendly with dividends (Helios $0.12/share, Apr27 record) and buybacks, but high debt growth (Belpointe +47% YoY) flags leverage concerns. Portfolio implication: Selective opportunities in outperforming revenue growers like Eli Lilly/Penske, monitor SPAC closes for volatility.

25 high priority 21 medium 46 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 20, 2026

Across 50 SEC filings from diverse sectors (despite Industrials focus, including media, pharma, banks, retail, and select industrials like GPC and GNK), key themes include mixed financial performance with revenue growth in 6/15 detailed reporters (avg +6% YoY, e.g., Dollar General +5.2%, QIAGEN +6%) offset by widening losses in 8/15 (avg +40% YoY, e.g., Urban One net loss +39%, Milestone Pharma +52%). M&A activity surges with accretive deals like Prestige's $1.045B Breathe Right acquisition (11x EBITDA, immediately accretive to EPS/FCF) and bank mergers (Stock Yards, Independent Bank), signaling consolidation. Capital allocation leans toward equity raises/financings (Benitec +92% cash, Palisade +$134M) amid cash burn concerns. Insider/leadership signals neutral with resignations (GPC CIO, FIS CPO) but positive appointments (Global Indemnity COO). Forward catalysts cluster in H1 2026: deal closes (Prestige H1 FY27), earnings (Civista Apr 22), AGMs (multiple Apr-May). Portfolio implication: Favor acquisitive consumer/health names over loss-making media/pharma; monitor bank NIM compression (Chain Bridge -7 bps).

29 high priority 21 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 20, 2026

Filings from the S&P 500 Energy stream reveal a mix of capital raising initiatives and modest operational updates in energy-adjacent sectors like oil tankers, with Okeanis Eco Tankers reporting a slight 0.4% YoY revenue decline to $391.5M for 2025 despite 1.3% TCE growth to $265.4M driven by 1.4% higher operating days at 5,025. Papa Medical's S-1/A signals IPO readiness with $15M gross proceeds targeted at $4/share, underscoring funding for hemp-derived products potentially tied to energy-alternative markets. Bioxytran completed a $1.2M private placement at $0.055/share, issuing 21M shares and warrants, reflecting positive sentiment amid working capital needs. AParadise Acquisition Corp.'s 425 filing promotes a SPAC merger with Enhanced Games, highlighting a May 24, 2026 catalyst event amid regulatory shift hopes for peptides. Portfolio-level trends show 1/4 filings with YoY revenue contraction (Okeanis -0.4%), but positive capital inflows averaging ~$10M+ per issuance; mixed sentiments dominate (50% mixed), with new issuances bullish. Key implication: Energy services face flat TCE rates (-0.1% YoY at $52,823), pressuring margins, while SPACs and placements offer entry points ahead of catalysts.

3 high priority 1 medium 4 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 20, 2026

Across 50 SEC filings from diverse sectors (despite Financials stream focus, data spans tech, health, retail, SPACs), mixed sentiment prevails in 70% of material filings (>5/10), with 12/20 10-Ks showing revenue growth averaging 72% YoY (e.g., Firefly +163%, Aeva +99%, Belpointe +244%) but net losses widening in 8/12 by avg 55% YoY due to op ex surges and impairments. Margin expansions noted in 5 cos (QIAGEN +1339bps gross, Latham +320bps, Dollar General +107bps), contrasting compression elsewhere; M&A/SPAC activity peaks with Embecta/Pelican deals closing soon, Prestige accretive acq. Capital allocation lean: News Corp $1B buyback ongoing, limited dividends/insider trades (no major buys/sells flagged). Proxy season ramps with 15+ AGMs Apr-May 2026 as catalysts; Financials-specific: Civista Q1 earnings Apr22, Metro Bank AI push/headcount +10%. Portfolio implication: Favor rev accelerators with margin inflection (Dollar General, Latham) over loss-makers; watch SPAC redemptions (Pelican 63%) for dilution risks.

34 high priority 16 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 20, 2026

Across the 8 S&P 500 Technology stream filings, dominant themes include robust revenue growth in core software players like Snowflake (29% YoY to $4.68B) contrasted with persistent operating losses and slight net retention declines, signaling scaling challenges amid high R&D and sales spend; governance and compensation disclosures in proxies like Cogent reveal mixed incentive achievements (152% AWR CAGR target hit but 79% GP) and large LTIP grants up to 551k RSUs for CEO, indicating long-term alignment. SPAC and name-change activities (dMY to Horizon Quantum, Muzero unit separation, AParadise merger promo) highlight quantum and tech-enabled merger momentum, though with unproven models and regulatory risks. Neutral proxy solicitations in non-core names like Genco and funds show routine governance without financial trends, while limited period-over-period data points to portfolio-level revenue acceleration (e.g., Snowflake's 42% RPO growth outlier) but stable-to-compressing margins (Snowflake gross 67% flat YoY, opex % improving modestly). Overall, mixed sentiment prevails with bullish growth signals outweighed by profitability concerns, creating opportunities in high-growth tech names ahead of catalysts like LTIP vesting and meetings. Critical implications: Investors should prioritize Snowflake's RPO momentum and Cogent's insider-aligned comp over SPAC risks, watching for Q1 2026 earnings to validate trends.

5 high priority 3 medium 8 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 20, 2026

Across 12 NASDAQ-100 related filings from March 20, 2026, proxy season dominates with 5 DEF/DEFA14A filings signaling imminent annual meetings and governance focus, while financial disclosures reveal mixed period-over-period trends: Zegna's FY2025 revenue declined 1.5% YoY to €1,917M but profit surged 20.5% YoY to €109M on 90 bps gross margin expansion; IPM reported FY2025 revenue of $23.6M with net loss down 42% YoY and Q4 Adjusted EBITDA turning positive post-transformation. Positive highlights include Gilead's robust HIV/oncology pipeline with up to 7 launches by 2033 and bulevirtide potential in 2026, AITX's new AI security order, and IPM's accretive acquisition adding 17k customers. Critical risks emerge in Faraday Future's Nasdaq delisting notice for sub-$1 bid price, granting 180 days to September 16, 2026, compliance. Portfolio-level patterns show profitability resilience amid revenue softness in luxury/shipping, SPAC liquidity/m erger progress, and limited insider details but LTIP grants signaling long-term alignment in Cogent/Gilead. Actionable implications favor monitoring pharma catalysts and avoiding delisting risks, with capital allocation tilting toward acquisitions/RSUs over dividends.

6 high priority 6 medium 12 total filings